TABLE I -.
Epidemiology, median progression-free survival and patient characteristics
| Data inputs | References | |
|---|---|---|
| Epidemiology of ALK-positive NSCLC | ||
| ALK+ NSCLC incidence (n) | 263 | (4,13-17) |
| Progression-free survival | ||
| Median PFS in ALK diagnosed patients with BM (months) | 25.4 | (6) |
| Median PFS in ALK diagnosed patients without BM (months) | 38.6 | (6) |
| Median PFS in ALK non-diagnosed patients with BM (months) | 5.8 | (6,18) |
| Median PFS in ALK non-diagnosed patients without BM (months) | 8.9 | (6,18) |
| Patient characteristics | ||
| Male (%) | 40.6 | (14) |
| Mean age at diagnosis (years) | 61 | (14) |
| Mean weight (kg) | 71.08 | (14,51) |
| Body surface (m2) | 1.79 | (14,51) |
| Creatinine level (mg/dL) | 0.7 | (52) |
| BM at diagnosis (%) | 42.11 | (6) |
ALK = anaplastic lymphoma kinase; BM = brain metastasis; NSCLC = non–small cell lung cancer; PFS = progression-free survival.